Expression and clinical significance of HMGB1 in human liver cancer: Knockdown inhibits tumor growth and metastasis in vitro and in vivo

Dong,Ya-Dong; Cui,Long; Peng,Cheng-Hong; Cheng,Dong-Feng; Han,Bao-San; Huang,Fang

doi:10.3892/or.2012.2070

Expression and clinical significance of HMGB1 in human liver cancer: Knockdown inhibits tumor growth and metastasis in vitro and in vivo

Authors:
- Ya-Dong Dong
- Long Cui
- Cheng-Hong Peng
- Dong-Feng Cheng
- Bao-San Han
- Fang Huang
View Affiliations

Affiliations: Department of General Surgery, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China
Published online on: October 4, 2012 https://doi.org/10.3892/or.2012.2070
Pages: 87-94

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The high-mobility group box 1 (HMGB1) signaling pathway plays a crucial role in tumorigenesis and progression of many malignant cancers. The present study aimed to investigate the expression and clinical significance of HMGB1 in human primary liver cancer, and further explore the molecular mechanisms of HMGB1 in tumor growth and metastasis. Forty cases of human liver cancer and normal liver tissues were collected. The expression of HMGB1 was assessed using RT-PCR and western blot assays in biopsy samples. The HMGB1 pathway in vitro was blocked using transfection of the recombinant small hairpin RNA adenovirus vector rAd5-HMGB1 into the human liver cancer cell line SMMC-7721. The expression of HMGB1, phosphorylated AKT (p-AKT), Ki-67 and matrix metallopeptidase-2 (MMP-2) was detected by Real-PCR and western blot assays. Cell proliferative activities and metastatic capability were determined by MTT and Transwell assays. Cell cycle distribution and apoptosis were detected by flow cytometry. A subcutaneous xenograft tumor model was established, validating the effects of rAd5-HMGB1 on tumor growth in vivo. As a consequence, HMGB1 was found to be highly expressed in liver cancer compared with normal tissues, and was positively associated with pathological grade and distant metastases of liver cancer. Knockdown of HMGB1 downregulated the expression of p-AKT, Ki-67 and MMP-2, inhibited the proliferative activities and metastatic potential of SMMC-7721 cells, induced cell cycle arrest and apoptosis, and slowed the growth of xenograft tumors. Altogether, the expression of HMGB1 is closely correlated with pathological grade and distant metastases of liver cancer, and knockdown of HMGB1 inhibits liver cancer growth and metastasis, suggesting that HMGB1 may be involved in liver cancer development and progression through AKT-mediated regulation of Ki-67 and MMP-2 expression, and represent a potential therapeutic target for this aggressive malignancy.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Tajima Y, Yamazaki K, Makino R, et al: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res. 12:6469–6479. 2006. View Article : Google Scholar
4	Sims GP, Rowe DC, Rietdijk ST, et al: HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
5	Okada H, Imai M, Ono F, et al: Novel complementary peptides to target molecules. Anticancer Res. 31:2511–2516. 2011.PubMed/NCBI
6	Takahata R, Ono S, Tsujimoto H, et al: Postoperative serum concentrations of high mobility group box chromosomal protein-1 correlates to the duration of SIRS and pulmonary dysfunction following gastrointestinal surgery. J Surg Res. 170:e135–e140. 2011. View Article : Google Scholar
7	Naglova H and Bucova M: HMGB1 and its physiological and pathological roles. Bratisl Lek Listy. 113:163–171. 2012.PubMed/NCBI
8	Lee H, Shin N, Song M, et al: Analysis of nuclear high mobility group box 1 (HMGB1)-binding proteins in colon cancer cells: clustering with proteins involved in secretion and extranuclear function. J Proteome Res. 9:4661–4670. 2010. View Article : Google Scholar : PubMed/NCBI
9	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 337:251–258. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wu D, Ding Y, Wang S, Zhang Q and Liu L: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol. 216:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chung HW, Lee SG, Kim H, et al: Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 7:382009. View Article : Google Scholar : PubMed/NCBI
13	Liu Y, Xie C, Zhang X, et al: Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer. 46:3007–3015. 2010. View Article : Google Scholar : PubMed/NCBI
14	Choi J, Lee MK, Oh KH, et al: Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori. 97:196–202. 2011.PubMed/NCBI
15	Moriwaka Y, Luo Y, Ohmori H, et al: HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology. 77:17–23. 2010. View Article : Google Scholar : PubMed/NCBI
16	Luo Y, Ohmori H, Fujii K, et al: HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. Eur J Cancer. 46:791–799. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yan W, Chang Y, Liang X, et al: High mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 55:1863–1875. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tafani M, Schito L, Pellegrini L, et al: Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis. 32:1167–1175. 2011.PubMed/NCBI
19	Chen J, Liu X, Zhang J and Zhao Y: Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 227:3629–3638. 2012. View Article : Google Scholar : PubMed/NCBI
20	Jiang W, Wang Z, Li X, et al: Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci. 57:92–98. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hanahan D and Weinberg RA: The hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
22	Lin L, Zhong K, Sun Z, et al: Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 138:11–22. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ohmori H, Luo Y and Kuniyasu H: Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011. View Article : Google Scholar : PubMed/NCBI
24	Peng RQ, Wu XJ, Ding Y, et al: Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO⁺ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer. 10:4962010. View Article : Google Scholar : PubMed/NCBI
25	Wild CA, Brandau S, Lotfi R, et al: HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol. 48:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
26	Cheng BQ, Jia CQ, Liu CT, et al: Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 40:446–452. 2008. View Article : Google Scholar : PubMed/NCBI
27	Liang X, Chavez AR, Schapiro NE, et al: Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol. 86:599–607. 2009. View Article : Google Scholar : PubMed/NCBI
28	Czyzewska J, Guzińska-Ustymowicz K, Lebelt A, et al: Evaluation of proliferating markers Ki-67, PCNA in gastric cancers. Rocz Akad Med Bialymst. 49(Suppl 1): 64–66. 2004.PubMed/NCBI
29	Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
30	Semba S, Moriya T, Kimura W and Yamakawa M: Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas. 26:250–257. 2003. View Article : Google Scholar : PubMed/NCBI
31	Zhang J, Zhang QY, Fu YC, et al: Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo. Technol Cancer Res Treat. 8:467–478. 2009. View Article : Google Scholar : PubMed/NCBI